济川药业子公司获康方伊努西单抗注射液独家商业化权益

Core Viewpoint - Jichuan Pharmaceutical has signed an exclusive commercialization rights agreement with Kangfang Biopharmaceutical, allowing Jichuan to exclusively commercialize the innovative drug Inusimab in China, excluding Hong Kong, Macau, and Taiwan [1] Group 1: Agreement Details - Jichuan Pharmaceutical's wholly-owned subsidiary will pay a total of 80 million yuan (including tax) as an authorization fee to Kangfang [1] - Additionally, Jichuan will pay up to 10 million yuan (including tax) in milestone payments [1] Group 2: Product Information - Inusimab is a PCSK9 monoclonal antibody developed by Kangfang, primarily used for treating primary hypercholesterolemia and mixed hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) and hypercholesterolemia with atherosclerotic cardiovascular disease [1] Group 3: Strategic Implications - The transaction is expected to enhance Jichuan's product line, contributing to the sustainable development of the company's business and aligning with its long-term strategic interests [1]